北京商报讯（记者 王寅浩 宋雨盈）2月27日，心脉医疗发布2025年业绩快报，2025年度公司实现营业总 收入13.51亿元，同比增长11.96%；归属于母公司所有者的净利润为5.63亿元，同比增长12.17%；归属 于母公司所有者的扣除非经常性损益的净利润为5.02亿元，同比增长26.97%；基本每股收益4.65元，同 比增长14.25%。 ...

人民财讯2月27日电，心脉医疗(688016)2月27日发布业绩快报，2025年实现营业总收入13.51亿元，同比 增长11.96%；归母净利润5.63亿元，同比增长12.17%；基本每股收益4.65元。报告期内，公司创新产品 在巩固国产领先优势的基础上，通过下沉市场、提供定制化治疗方案以及产品升级迭代，加速推广新 品、替换老产品等策略，推动市占率稳步提升，但考虑到2024年市场价格治理因素影响的延续性，公司 部分产品价格及推广策略的调整因素，全年销售额增速及利润仍受到一定影响。 ...

报告期内，公司海外销售收入超过2.5亿元，同比增长超过55%，在公司收入占比提升至18%以上，并且 公司持续推动全球范围内与区域行业领先客户的合作，持续推进主动脉及外周介入产品在欧洲、拉美、 亚太等国家的市场准入和推广工作。截至报告期末，公司产品销售覆盖49个国家和地区（含中国）。 格隆汇2月27日丨心脉医疗(688016.SH)公布2025年年度业绩快报，报告期内，公司实现营业总收入13.51 亿元，同比增长11.96%；归属于母公司所有者的净利润5.63亿元，同比增长12.17%；归属于母公司所有 者的扣除非经常性损益的净利润5.02亿元，同比增长26.97%；基本每股收益4.65元，同比增长14.25%。 报告期内，公司创新产品在巩固国产领先优势的基础上，通过下沉市场、提供定制化治疗方案以及产品 升级迭代，加速推广新品、替换老产品等策略，推动市占率稳步提升，但考虑到2024年市场价格治理因 素影响的延续性，公司部分产品价格及推广策略的调整因素，全年销售额增速及利润仍受到一定影响。 ...

报告期内，公司创新产品在巩固国产领先优势的基础上，通过下沉市场、提供定制化治疗方案以及产品 升级迭代，加速推广新品、替换老产品等策略，推动市占率稳步提升，但考虑到2024年市场价格治理因 素影响的延续性，公司部分产品价格及推广策略的调整因素，全年销售额增速及利润仍受到一定影响。 格隆汇2月27日丨心脉医疗(688016.SH)公布2025年年度业绩快报，报告期内，公司实现营业总收入13.51 亿元，同比增长11.96%；归属于母公司所有者的净利润5.63亿元，同比增长12.17%；归属于母公司所有 者的扣除非经常性损益的净利润5.02亿元，同比增长26.97%；基本每股收益4.65元，同比增长14.25%。 报告期内，公司海外销售收入超过2.5亿元，同比增长超过55%，在公司收入占比提升至18%以上，并且 公司持续推动全球范围内与区域行业领先客户的合作，持续推进主动脉及外周介入产品在欧洲、拉美、 亚太等国家的市场准入和推广工作。截至报告期末，公司产品销售覆盖49个国家和地区（含中国）。 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2026-004 二、经营业绩和财务状况情况说明 上海微创心脉医疗科技（集团）股份有限公司 2025 年年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 1,350,632,689.26 | 1,206,326,728.85 | 11.96% | | 营业利润 | 653,891,743.30 | 661,172,432.85 | -1.10% | | 利润总额 | 653,374,650.83 | 652,193,918.34 | 0.18% | | 归属于母公司所有者的净 利润 | 563,213,12 ...

Core Viewpoint - The company has received regulatory approval for its first embolic product in the tumor intervention field, which is expected to enhance its product pipeline, although actual sales impact remains uncertain until production licenses are obtained [1] Recent Events - A national centralized procurement for 316 commonly used drugs, including those for anti-tumor treatments, has been initiated, with a selection rate of 93%. This may exert price pressure on the pharmaceutical industry, and the company should be aware of the risks associated with high-value consumables procurement expansion [2] Stock Performance - The company's stock price fluctuated between a high of 100.00 yuan and a low of 97.60 yuan over the past week, with a total price change of 1.21% and a volatility of 2.46% [3] Capital Movement - There was a net outflow of 197.72 million yuan in main funds on February 5, with a significant single purchase accounting for 6.03%. The total trading volume over the past week was 619 million yuan, indicating active turnover, while the medical device sector saw a slight decline of 0.48% [4] Financial Report Analysis - For the first three quarters of 2025, the company reported revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, while net profit decreased by 22.46% to 429 million yuan. The gross margin stood at 70.4%, with a significant revenue increase of 64.68% in the third quarter, although net profit was impacted by product price adjustments [5] Financial Condition - The company has a debt ratio of 15.85% and maintains a stable cash flow, with overseas business revenue accounting for 18% of total income in the first three quarters, expected to grow over 60% for the year [6] Institutional Viewpoints - Analysts suggest that while short-term profitability may be under pressure, the company is likely to benefit from innovative product iterations, accelerated overseas expansion, and domestic substitution trends in the medium to long term, with a target price of 122.06 yuan. However, caution is advised regarding procurement policies and potential underperformance in R&D [7]

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 98.3 yuan as of February 9, 2026, indicating a 0.33% rise. The trading volume was 9,421 lots, with a total transaction value of 92.59 million yuan [1]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%. However, the net profit attributable to shareholders decreased by 22.46% to 429 million yuan, and the net profit after deducting non-recurring gains and losses fell by 25.8% to 372 million yuan [1]. - In the third quarter of 2025, the company achieved a single-quarter main revenue of 300 million yuan, which is a significant year-on-year increase of 64.68%. The single-quarter net profit attributable to shareholders was 114 million yuan, down 23.63%, while the net profit after deducting non-recurring gains and losses was 102 million yuan, a decrease of 11.84% [1]. - The company's debt ratio stands at 15.85%, with investment income of 11.6 million yuan and financial expenses of -7.86 million yuan. The gross profit margin is reported at 70.4% [1]. Market Sentiment - Over the last 90 days, three institutions have provided ratings for the stock, all of which are buy ratings [2]. - On February 9, 2026, the net outflow of main funds was 1.7167 million yuan, accounting for 1.85% of the total transaction value. The net outflow of speculative funds was 634,800 yuan, representing 0.69% of the total transaction value, while retail investors saw a net inflow of 2.3515 million yuan, making up 2.54% of the total transaction value [1].

Core Viewpoint - The company, Xinmai Medical, has seen a stock price increase of 3.1% this week, closing at 97.98 yuan, with a total market capitalization of 12.077 billion yuan, ranking 27th in the medical device sector and 1716th in the A-share market [1] Company Announcements - Xinmai Medical's wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate for polyvinyl alcohol embolization microspheres, intended for the treatment of hypervascular solid organ malignant tumors [1] - This product marks the company's first embolization product in the field of tumor interventional therapy, with the registration certificate valid from January 28, 2026, to January 27, 2031 [1] - The company has multiple other tumor interventional products that have been approved or are under research, but actual sales will depend on market promotion efforts, making future revenue impact unpredictable [1]

中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 2025 年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引 第11号——持续督导》等有关法律、法规的规定，中国国际金融股份有限公司（以下简 称"保荐机构"、"中金公司"）作为正在履行上海微创心脉医疗科技（集团）股份有 限公司（以下简称"心脉医疗"、"公司"）持续督导工作的保荐机构，对公司2025年 1月1日至2025年12月31日期间（以下简称"本持续督导期间"）的规范运作情况进行了 现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构：中国国际金融股份有限公司 （五）现场检查内容：公司治理及内部控制、信息披露、独立性、与关联方的资金 往来、募集资金使用情况、关联交易、对外担保、重大对外投资、公司经营状况等。 （六）现场检查手段:对公司董事会秘书、财务总监等进行访谈；查看公司主要经 营、管理场所；查阅并取得公司公告、公司治理文件、重大合同、公司定期报告等文件； 查阅并取得公司募集资金使用凭证等原始凭证、募集资金专户银行对账单等资料；查阅 公司本持续督导 ...

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 99.25 yuan on February 5, 2026, reflecting a 1.66% rise, while the overall market sentiment indicates mixed capital flows with significant retail investor inflow [1][5]. Financial Performance - Xinmai Medical reported a total revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66% [4]. - The net profit for the same period was 429 million yuan, showing a year-on-year decline of 22.46% [4]. - The gross profit margin stands at 70.4%, significantly higher than the industry average of 50.55% [4]. Market Position - Xinmai Medical's total market capitalization is 12.234 billion yuan, which is above the industry average of 11.126 billion yuan, ranking 27th out of 128 companies in the medical device sector [4]. - The company has a price-to-earnings (P/E) ratio of 21.38, which is considerably lower than the industry average of 93.58, ranking 13th in the industry [4]. Capital Flow Analysis - On February 5, 2026, the net outflow of main funds was 10.8214 million yuan, accounting for 4.87% of the total transaction amount, while retail investors saw a net inflow of 15.6052 million yuan, representing 7.02% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with notable retail investor activity during periods of price increases [1][2]. Institutional Ratings - In the last 90 days, four institutions have issued buy ratings for Xinmai Medical, with an average target price of 122.06 yuan [5].